Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Public ClinicalTrials.gov record NCT05757713. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants <8 Years of Age With at Least Two Autoantibodies and Dysglycemia)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
Study identification
- NCT ID
- NCT05757713
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 0 Years to 7 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 25, 2023 (Actual)
- Primary completion
- Aug 28, 2026 (Actual)
- Completion
- Aug 28, 2026 (Actual)
- Last update posted
- Sep 29, 2026
2023 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Medical Center Site Number : 107 | San Francisco | California | 94143 | — |
| Barbara Davis Center for Diabetes Site Number : 102 | Aurora | Colorado | 80045 | — |
| Yale University School of Medicine Site Number : 101 | New Haven | Connecticut | 06511 | — |
| Centricity Research Site Number : 104 | Columbus | Georgia | 31904 | — |
| Indianapolis University Health Riley Hospital for Children Site Number : 110 | Indianapolis | Indiana | 46202 | — |
| UBMD Pediactrics Site Number : 105 | Buffalo | New York | 14203 | — |
| Children's Hospital of Philadelphia Site Number : 108 | Philadelphia | Pennsylvania | 19104 | — |
| Sanford Diabetes and Thyroid Clinic Site Number : 106 | Sioux Falls | South Dakota | 57105 | — |
| Vanderbilt Univerity Medical Center Site Number : 109 | Nashville | Tennessee | 37232 | — |
| MulitCare Institute for Research & Innovation Site Number : 103 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05757713, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05757713 live on ClinicalTrials.gov.